https://asiaactual.com/wp-content/uploads/2020/04/shutterstock_566269936-scaled.jpg17082560Mark Weisbrodhttps://asiaactual.com/wp-content/uploads/2020/08/Growing-Medical-Device-Sales-1030x257.gifMark Weisbrod2020-07-23 15:10:482020-10-21 17:05:28U.S. Medical Device Industry – Open for Business
https://asiaactual.com/wp-content/uploads/2020/07/shutterstock_222293677-scaled.jpg17092560Eric Leunghttps://asiaactual.com/wp-content/uploads/2020/08/Growing-Medical-Device-Sales-1030x257.gifEric Leung2020-07-10 23:17:192020-10-29 18:14:44Voluntary Medical Device Registration in Hong Kong
Medical device manufacturers are advised to prepare e-Catalogue applications early and be vigilant for the enrollment announcement. Implementing an optimal pricing strategy will be critical to successful public hospital sales. The e-Catalogue system also increases the importance of independent license holding in Indonesia because there is little room for regional dealer margin under the price scheme.
The PCSO is a major source of funding for new hospital construction and medical device and equipment purchases and is often overlooked by outside suppliers. Medical device manufacturers should discuss with their Philippines distributors about what opportunities are available through the PCSO.
By allowing manufacturers to show conformity to the MDD’s assessment requirements by using NMPA or MFDS approvals, Chinese and Korean manufacturers would save 6-9 months during the application process.
https://asiaactual.com/wp-content/uploads/2020/06/shutterstock_1505193107-scaled.jpg17072560Bryan Gilburghttps://asiaactual.com/wp-content/uploads/2020/08/Growing-Medical-Device-Sales-1030x257.gifBryan Gilburg2020-06-10 20:00:492020-09-22 18:05:34HONG KONG EXTENDS PILOT PROGRAM TO RECOGNIZE CHINA AND KOREA AS REFERENCE COUNTRIES
On July 1st, 2020 the Malaysia Medical Device Authority (MDA) will implement the Medical Device (Duties and Obligations of Establishment) Regulations 2019, implementing guidelines for Adverse Event (AE) Reporting within the current mandatory registration system.
Asia Actual works with highly experienced professionals in China that can provide you with accurate and timely Risk Assessment reports for your products that will not only satisfy the NMPA’s requirements but could also be used for updating Clinical Evaluation Reports in other markets.